BOARD OF DIRECTORS
Lee Babiss, PhD
Dr. Babiss is CEO of X-Rx Inc., a PPD-majority owned Biotech that focuses on developing innovative early stage drugs in the areas of Oncology, Fibrosis and Autoimmune diseases. Prior to this, Lee was PPD's chief scientific officer and executive vice president of discovery innovation.
Babiss joined PPD in 2010 with more than 21 years of experience in leading R&D efforts in support of drug discovery. He most recently served as president and director of pharmaceutical research for F. Hoffmann-La Roche Ltd., in Basel, Switzerland, where his responsibilities included leading global laboratory functions in chemistry, discovery technologies, therapeutic proteins, non-clinical safety and informatics. He supported drug discovery efforts in oncology, neurosciences, inflammation, virology and metabolism, and was a member of the company’s pharma executive and strategic portfolios committees.
Prior to joining Hoffmann-La Roche, Babiss spent seven years with Glaxo Inc., now GlaxoSmithKline. As vice president of biological sciences and genetics, he had global accountability for developing and implementing the company’s corporate genetics strategy and oncology research efforts focused on the cell cycle.
Babiss earned a doctorate in microbiology from Columbia University and completed his postdoctoral fellowship at The Rockefeller University, where he served as an assistant and associate professor. He has published more than 60 peer-reviewed scientific papers, received numerous fellowship awards and grants, and serves on several scientific advisory committees and boards.
Ronald W. Barrett, PhD
Barrett is a scientist entrepreneur with more than 30 years experience in the biopharmaceutical industry. He is the former CEO and a Director of XenoPort, Inc, a biopharmaceutical-focused company he co-founded in 1999, which was acquired by Arbor Pharmaceutical in 2016. Under Barrett’s guidance, XenoPort advanced five in-house discovered compounds into human trials including mid- to late-stage clinical trials for the treatment of restless legs syndrome (RLS), post-herpetic neuralgia, painful diabetic neuropathy, migraine prophylaxis, alcohol use disorder, spasticity associated with multiple sclerosis and spinal cord injury, gastroesophageal reflux, Parkinson’s disease and psoriasis. Barrett led the company’s efforts that resulted in the FDA approval of HORIZANT (gabapentin enacarbil), the first and only non-dopaminergic drug approved for moderate to severe RLS.
Prior to founding XenoPort, Barrett was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to 2 FDA-approved medicines. Barrett began his professional career in the neuroscience drug discovery group at Abbott Laboratories. He is currently Executive Chairman of Medikine Inc, and a Director of Concert Pharmaceuticals, Inc. (Nasdaq:CNCE). He is currently Director of the RLS Foundation, a non-profit patient advocacy group and previously served as a Director of the Youth Science Institute, a non-profit focused on K-8 science education. Barrett has co-authored >50 manuscripts from peer-reviewed journals and is an inventor of >50 issued patents in the U.S. He received a BS degree in biology from Bucknell University and a Ph.D degree in pharmacology from Rutgers University.
Gordon Ringold, PhD, CEO
Gordon is a biotechnology entrepreneur. Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is currently on the board of directors for Maverix Biomics, a bio-informatics company co-founded by Prof Todd Lowe (UCSC) and is on the board of directors of Ardelyx, Alexza, and 3V Biopharma.. From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Gordon was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies to accelerate the pace of drug discovery; prior to that he was VP and Director of the Institute for Cancer and Developmental Biology at Syntex Corporation (1986-1991). Gordon received his Ph.D. in the laboratory of Dr. Harold Varmus, before joining the Stanford University School of Medicine, Department of Pharmacology (1978-1987). While on the Stanford faculty he invented technologies for manufacturing of recombinant proteins in mammalian cells, now widely used for production of dozens of therapeutic products and received the John J. Abel Award as the best Pharmacologist in the US under the age of 35. Gordon is an alumnus of Crown College, UC Santa Cruz, 1972.
Kerry J. Koller, PhD, VP Pharmacology
Kerry is one of our founders and the Vice President of Molecular Pharmacology. She has nearly 30 years experience working in biotechnology, focusing primarily on transporter and receptor biology. Her discovery and development expertise includes target ID, assay development, candidate selection, and IND-enabling studies.
Prior to Quadriga, Kerry held positions of increasing responsibility at Genentech, Affymax, and XenoPort, where she was most recently Senior Director of Discovery Biology. Kerry graduated with a B.S. in Chemistry, Honors, from Stanford University. She received her Ph.D. in Biochemistry/Neuropharmacology at the Johns Hopkins University School of Medicine. She is an author and inventor on over 40 scientific papers and patents.
Peter Y. Tam, MBA, President & COO
Peter is a pharmaceutical executive with over 25 years of drug development experience. He is currently President and COO of Quadriga Biosciences. Prior to joining Quadriga, Peter served as President and a member of the Board of Directors of VIVUS Inc, a biopharmaceutical company that develops therapies for the treatment of obesity, diabetes, and urology. Under his leadership, VIVUS obtained four consecutive drug approvals from product inception. Peter built the company’s R&D pipeline through licensing and acquisition. He built and led R&D teams (regulatory, clinical and CMC), created and developed patent portfolio and collaborated with FDA, corporate partners and stakeholders to ensure regulatory approvals for company's pipeline products. He also helped raise over $500M in corporate financing during his 20-year tenure at VIVUS (1993-2012). He has extensive management experience in drug development , corporate/business development, senior executive leadership and board experience in the biopharmaceutical industry. Prior to VIVUS, Peter also held various research and clinical development positions at Genentech and XOMA Corporation.
Peter holds a B.S. in Chemistry from University of California Berkeley and an MBA from Santa Clara University. He has a number of patents approved and pending to his name.
Wolf-Nicolas Fischer, PhD, VP Biology
Dr. Fischer is a co-founder of Quadriga BioSciences, Inc. and serves as Quadriga’s VP of Biology. For more than 25 years, Dr. Fischer focused his research on the SAR of membrane transporters of various different species. Dr. Fischer’s expertise ranges from bench scientist to technical entrepreneur. Before co-founding Quadriga BioSciences, Dr. Fischer was a distinguished Principal Investigator at XenoPort, a leader in the design of actively transported pro-drugs. During his tenure at XenoPort from 2001-2010, Dr. Fischer and his team determined the SAR of numerous transporters, which established the foundation of XenoPort's Transported Prodrugs™ technology platform. He and his team worked on various R&D programs, ranging from metabolic diseases, to infectious diseases and CNS syndromes, including schizophrenia, depression and alcoholism. From 1999 to 2001, Dr. Fischer headed the Plant Nutrition at Paradigm Genetics, Inc., a Genomics based company located in Research Triangle Park. The focus of his group was to maximize product quality and yield by optimizing nutrient acquisition and distribution within plants via modified membrane transporter expression. Prior to Paradigm Genetics, Dr. Fischer held various positions at the Max-Planck Institute for Molecular Genetics (Institut für Genbiologische Forschung, Berlin Germany), Eberhard-Karls University (Tübingen, Germany) and UCLA School of Medicine (Los Angeles, California). Dr. Fischer received his Ph.D. in Biology form the University of Eberhard Karls University Tübingen (Germany) and his M.S. in Chemistry from the Technical University Berlin (TU-Berlin, Germany).
Berndt Jandeleit, PhD, VP Chemistry
Dr. Jandeleit is a co-founder of Quadriga BioSciences, Inc. and serves as Quadriga’s VP of Chemistry since conception of the company in late 2010. Dr. Jandeleit’s career spans more then 20 years in the biopharmaceutical and life sciences industries. From 2000 to 2010, he worked at XenoPort, Inc., a company engaged in improving the clinical utility of medicines by exploiting active transport mechanisms to optimize pharmacokinetic properties of drugs. As an Associate Director, he was as a project leader for multiple R&D programs in a variety of therapeutic areas. He was also essential in profiling prevalence and specificity of solute carrier nutrient transporters for drug delivery for XenoPort's Transported Prodrugs™ technology platform. From 1997 to 2000, he served as a Sr. Staff Scientist and Lead Organic Chemist at Symyx Technologies, Inc. (now Accelerys, Inc.), a pioneer in combinatorial and high-throughput R&D approaches toward catalysis and materials science. As a fellow of the German National Scholarship Foundation and BASF AG, he conducted postdoctoral research from 1995 to 1997 in the labs of Prof. K.C. Nicolaou at The Scripps Research Institute, La Jolla. Dr. Jandeleit received his MS and PhD degrees, both withsumma cum laude, from the RWTH Aachen University in Germany with Prof. D. Enders. He was awarded the Borcher's Batch and theSpringorum Medal. He is an inventor on more then 20 granted national and international patents, numerous pending US and PCT patent applications, and a co-author on over 30 publications in peer-reviewed journals. Several of his molecules were licensed to pharmaceutical companies including tranexamic acid prodrug XP21510 that was licensed an aggregate of $147M.